# Bio2 Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bio2-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Woburn, US
- Website: www.bio2tech.com
- Total disclosed funding: $5.6M
- Latest round: Series C (Sep 11, 2018)
- Investors on record: 2

## About

Bio2 Technologies, Inc. develops innovative biomaterial solutions utilizing patented CLM technology. Their advanced products aim to enhance surgical outcomes in the healthcare sector, specifically in musculoskeletal surgery.Bio2 Technologies, Inc. specializes in creating advanced biomaterial solutions and was founded in 2009 in Woburn, US. The company has conducted a total of 4 deals, with the most recent deal occurring on August 26, 2019, where they raised USD 4.308 mn in venture funding. Their CEO, Tom Afzal, leads the company in their mission to improve healthcare using innovative materials.Bio2 Technologies, Inc. specializes in advanced biomaterial solutions, primarily through its patented CLM technology, which utilizes bioactive glass as its core component. This technology addresses critical needs in the healthcare sector, specifically within the musculoskeletal surgery market. Bio2’s products promote better healing and integration within the body, targeting healthcare providers and surgical facilities seeking to improve patient care. Their products are marketed in North America and Europe, catering to hospitals, orthopedic surgeons, and rehabilitation centers.Bio2 Technologies operates through a direct-to-consumer model and B2B partnerships, focusing on delivering its flagship CLM technology to healthcare providers. Revenue is generated primarily from sales of its biomaterial products, structured around individual transactions and bulk orders for larger healthcare institutions. Specific details on pricing structures or contractual terms are not publicly disclosed; however, efficient procurement processes are facilitated for end-users, which include surgical centers and hospitals.Bio2 Technologies plans to leverage its recent funding of USD 4.308 mn raised in August 2019 to develop new products and expand its reach into new geographic markets. The company is targeting further development of its CLM technology, with a focus on enhancing applications in the healthcare sector. This strategic expansion will likely include entering additional European markets and potentially exploring opportunities in Asia by 2022.

## Funding rounds

- Series C, Sep 11, 2018, $4.5M — DSM Venturing
- Series A, Jun 28, 2010, $1.1M — Hamilton BioVentures

## Investors

- Hamilton BioVentures (https://capitalatlas.ai/funds/hamilton-bioventures) — Series A
- DSM Venturing (https://capitalatlas.ai/funds/dsm-venturing) — Series C